Abnova Launches Innovative Oligo(dT) IVT mRNA Purification Instrument, Spiraltor™ 48
Neihu, Taiwan (April 12, 2023)
Abnova announced the launch of its innovative Oligo(dT) IVT (in vitro transcription) mRNA purification instrument, Spiraltor™ 48, which utilizes advanced Oligo(dT) magnetic bead separation and column rotation technologies. By binding the Oligo(dT) on the magnetic beads to the poly(A) sequence in the target mRNA. Spiraltor™ 48 can separate IVT mRNA from impurities such as DNA and proteins, achieving efficient, fast, and accurate purification, thereby improving production quality and experimental efficiency.
The rapid development of mRNA vaccines during the COVID-19 pandemic has increased the demand for IVT mRNA technology, which is now being widely applied in various areas such as cancer, rare diseases, and chronic diseases. The expanding application demand has driven the need for enzymes, reagents, and automated instruments in the IVT mRNA production process. However, conventional Oligo(dT) manual purification methods still suffer from uncertainties such as batch variations and operator errors, which can negatively impact experimental results. Spiraltor™ 48 overcomes these limitations by using an intelligent control system and a unique rotating column technology, thereby enhancing purification efficiency and production quality while reducing batch variation. With its intuitive user interface, users can easily change parameters to provide reproducible and consistent results, thereby minimizing the drawbacks of manual operation.
Leveraging its experience in COVID-19 mRNA vaccine development and its proprietary non-viral vector technology platform for creating next-generation mRNA therapies, Abnova has introduced the innovative Oligo(dT) IVT mRNA purification instrument, Spiraltor™ 48. This convenient and innovative technology improves IVT mRNA output purity and stability, helping laboratory personnel accelerate mRNA drug and vaccine development. With the growing demand for accessories, reagents, and batch automation instruments in the IVT mRNA market, Spiraltor™ 48 provides a broad development prospect for the IVT mRNA research market, becoming an indispensable instrument in the IVT mRNA product production process.
+886-2-87511888
sales@abnova.com
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)